Related references
Note: Only part of the references are listed.Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial
Thomas Van Stappen et al.
GUT (2018)
Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of RemicadeA®
Joseph C. Marini et al.
AAPS JOURNAL (2017)
Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay
Thomas Van Stappen et al.
DRUG TESTING AND ANALYSIS (2017)
American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases
Niels Vande Casteele et al.
GASTROENTEROLOGY (2017)
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2017)
A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease
Johannan F. Brandse et al.
INFLAMMATORY BOWEL DISEASES (2017)
Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease
Yun Qiu et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease
Adam Frymoyer et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2017)
Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease
Tatyana Hofmekler et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2017)
Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics
Sara Murias et al.
THERAPEUTIC DRUG MONITORING (2017)
Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview
Pieter Hindryckx et al.
DRUGS (2017)
Review article: dose optimisation of infliximab for acute severe ulcerative colitis
P. Hindryckx et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease
Thomas Billiet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
Johannan F. Brandse et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease
Adam Frymoyer et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2016)
The underlying inflammatory chronic disease influences infliximab pharmacokinetics
Christophe Passot et al.
MABS (2016)
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes
Murli Krishna et al.
FRONTIERS IN IMMUNOLOGY (2016)
Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases
K. Papamichael et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
L. Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis
Maria Theresa Arias et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Johannan F. Brandse et al.
GASTROENTEROLOGY (2015)
Antibodies to Infliximab Are Associated with Lower Infliximab Levels and Increased Likelihood of Surgery in Pediatric IBD
Naamah L. Zitomersky et al.
INFLAMMATORY BOWEL DISEASES (2015)
Extraintestinal Manifestations of Inflammatory Bowel Disease
Stephan R. Vavricka et al.
INFLAMMATORY BOWEL DISEASES (2015)
Pharmacokinetics of Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Adding Value to Current Practice
Niels Vande Casteele et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Infliximab-Related Infusion Reactions: Systematic Review
Lev Lichtenstein et al.
JOURNAL OF CROHNS & COLITIS (2015)
Inflammatory bowel disease pathogenesis: Where are we?
Claudio Fiocchi
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease
Daniel R. Hoekman et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2015)
Inflammatory Bowel Disease in Children and Adolescents
Michael J. Rosen et al.
JAMA PEDIATRICS (2015)
Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis
David Ternant et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2014)
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial
Casper Steenholdt et al.
GUT (2014)
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
Bella Ungar et al.
GUT (2014)
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
Freddy Cornillie et al.
GUT (2014)
Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study
Iris Dotan et al.
INFLAMMATORY BOWEL DISEASES (2014)
Challenges in Designing a National Surveillance Program for Inflammatory Bowel Disease in the United States
Millie D. Long et al.
INFLAMMATORY BOWEL DISEASES (2014)
A 10-Year, Single Tertiary Care Center Experience on the Durability of Infliximab in Pediatric Inflammatory Bowel Disease
Elaheh Vahabnezhad et al.
INFLAMMATORY BOWEL DISEASES (2014)
Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Sorcha O'Meara et al.
INFLAMMATORY BOWEL DISEASES (2014)
Infliximab Maintains Durable Response and Facilitates Catch-up Growth in Luminal Pediatric Crohn's Disease
Peter C. Church et al.
INFLAMMATORY BOWEL DISEASES (2014)
Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease: Results from a Pilot Observational Study
Byron P. Vaughn et al.
INFLAMMATORY BOWEL DISEASES (2014)
Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease
Namita Singh et al.
INFLAMMATORY BOWEL DISEASES (2014)
Treatment of complex perianal fistulas with seton and infliximab in adolescents with Crohn's disease
Maria Hukkinen et al.
JOURNAL OF CROHNS & COLITIS (2014)
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Niels Vande Casteele et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation
Pauline A. van Schouwenburg et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study
Stephane Paul et al.
INFLAMMATORY BOWEL DISEASES (2013)
Pharmacokinetics of Infliximab in Children with Moderate-to-Severe Ulcerative Colitis: Results from a Randomized, Multicenter, Open-label, Phase 3 Study
Omoniyi J. Adedokun et al.
INFLAMMATORY BOWEL DISEASES (2013)
Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay
Shui-Long Wang et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2013)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
Rong Deng et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Therapeutic drug monitoring of biologics for inflammatory bowel disease
Jean-Frederic Colombel et al.
INFLAMMATORY BOWEL DISEASES (2012)
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum
Shui-Long Wang et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing 'top-down' and 'step-up' strategies
Mi Jin Kim et al.
ACTA PAEDIATRICA (2011)
Assessing Response and Loss of Response to Biological Therapies in IBD
Henit Yanai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists
Hilbert S. de Vries et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease
Matthias Jurgens et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
Adedigbo A. Fasanmade et al.
CLINICAL THERAPEUTICS (2011)
Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
A.A. Fasanmade et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C. H. Seow et al.
GUT (2010)
Prospective Evaluation of Anti-Tumor Necrosis Factor Therapy Guided by Magnetic Resonance Imaging for Crohn's Perineal Fistulas
Siew C. Ng et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis
Trine Olsen et al.
CYTOKINE (2009)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Efficacy of Infliximab in Pediatric Crohn's Disease: A Randomized Multicenter Open-label Trial Comparing Scheduled to On Demand Maintenance Therapy
Frank M. Ruemmele et al.
INFLAMMATORY BOWEL DISEASES (2009)
Incidence and Clinical Significance of Immunogenicity to Infliximab in Crohn's Disease: A Critical Systematic Review
Andrea Cassinotti et al.
INFLAMMATORY BOWEL DISEASES (2009)
Infliximab Therapy in Children With Concurrent Perianal Crohn Disease: Observations From REACH
Wallace Crandall et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2009)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Daniel Tracey et al.
PHARMACOLOGY & THERAPEUTICS (2008)
The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States
Michael D. Kappelman et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Jeffrey Hyams et al.
GASTROENTEROLOGY (2007)
Clinical pharmacokinetics and use of infliximab
Ulrich Klotz et al.
CLINICAL PHARMACOKINETICS (2007)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis
GJ Wolbink et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Premedication and infusion reactions with infliximab: Results from a pediatric inflammatory bowel disease consortium
DA Jacobstein et al.
INFLAMMATORY BOWEL DISEASES (2005)
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease
GR Lichtenstein et al.
GASTROENTEROLOGY (2005)
Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins
D Ternant et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2005)
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease
E Louis et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease
JMH Van Den Brande et al.
GASTROENTEROLOGY (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model
WV Crandall et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Share Paper
